Most studies investigating therapeutic response towards ICIs in bladder cancer have focused on tumor-intrinsic mechanisms (e.g., TGF-β1, or Wnt/β-catenin)15,19,20. This evidence concerns the gene TGFB1 and urinary bladder carcinoma.